{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:43:32Z","timestamp":1775097812629,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clml.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T19:16:35Z","timestamp":1487272595000},"page":"238-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"17","author":[{"given":"Erna","family":"Islamagic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azra","family":"Hasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabira","family":"Kurtovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emina","family":"Suljovic Hadzimesic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lejla","family":"Mehinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirza","family":"Kozaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Kurtovic-Kozaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.001_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.001_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155214522143","article-title":"Clinical efficacy of generic imatinib","volume":"21","author":"de Lemos","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2017.02.001_bib3","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.3109\/10428194.2014.921299","article-title":"Generic imatinib: the real-deal or just a deal?","volume":"55","author":"Mathews","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.02.001_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jps.22772","article-title":"Conformational polymorphism on imatinib mesylate: grinding effects","volume":"101","author":"Grillo","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.clml.2017.02.001_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-008-0778-7","article-title":"Effect of antacid on imatinib absorption","volume":"63","author":"Sparano","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2017.02.001_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5604\/20828691.1123442","article-title":"Original vs generic drugs in treatment of chronic myeloid leukemia","volume":"4","author":"Rusicka","year":"2014","journal-title":"OncoReview"},{"key":"10.1016\/j.clml.2017.02.001_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/17474086.2014.966679","article-title":"Generics in chronic myeloid leukemia: current arguments for and against and the established evidence","volume":"7","author":"Soysal","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2017.02.001_bib8","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3109\/10428194.2014.904508","article-title":"Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back","volume":"55","author":"Alwan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.02.001_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/2277-9175.108000","article-title":"Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia","volume":"2","author":"Moshfeghi","year":"2013","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.clml.2017.02.001_bib10","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1182\/blood.V124.21.5527.5527","article-title":"Impact of transition to generic imatinib in the molecular response among patients with chronic myeloid leukemia","volume":"124","author":"Kang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.001_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4999\/uhod.1111","article-title":"Generic imatinib mesylate is as effective as original Glivec in the clinical management of CML","volume":"4","author":"Malkan","year":"2015","journal-title":"UHOD"},{"key":"10.1016\/j.clml.2017.02.001_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.02.001_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.13843","article-title":"The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukemia patients","volume":"172","author":"Kurtovic-Kozaric","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.001_bib14","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.001_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clml.2016.04.003","article-title":"Comparison of branded and generic imatinib plasma concentrations in patients with chronic myelogenous leukemia: unicentric study","volume":"16","author":"Ostojic","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.02.001_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.clml.2016.09.006","article-title":"Effects of deeper molecular responses on outcomes in chronic myeloid leukemia patients in chronic phase treated with imatinib mesylate","volume":"17","author":"Kaygusuz Atagunduz","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016308849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016308849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:08Z","timestamp":1761870488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016308849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S2152265016308849"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}